Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ludger Klimek, Jean Bousquet & David Price. (2016) Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Expert Opinion on Drug Safety 15:1, pages 117-129.
Read now
Read now
Cristoforo Incorvaia, Philippe Moingeon, Serena Buttafava & Franco Frati. (2015) Focusing the mechanism of action to dissect the different treatments of respiratory allergy. Expert Review of Clinical Immunology 11:9, pages 1005-1013.
Read now
Read now
Articles from other publishers (13)
Abdullah Al-Shamrani, Saleh Alharbi, Sumayyah Kobeisy, Suzan A. AlKhater, Haleimah Alalkami, Turki Alahmadi, Aisha Almutairi, Adel S. Alharbi & Abdullah A. Yousef. (2022) Adverse Drug Reactions (ADRs) of Montelukast in Children. Children 9:11, pages 1783.
Crossref
Crossref
Abdullah Al Shamrani, Ayshah AlShammari, Halima AlAlkami, Jawaher AlShanwani & Adel S. Alharbi. (2021) When is asthma not guilty?. International Journal of Pediatrics and Adolescent Medicine 8:4, pages 203-211.
Crossref
Crossref
I. Kortekaas Krohn, I. Callebaut, Y. A. Alpizar, B. Steelant, L. Van Gerven, P. S. Skov, A. Kasran, K. Talavera, M. M. Wouters, J. L. Ceuppens, S. F. Seys & P. W. Hellings. (2018) MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy 73:5, pages 1084-1093.
Crossref
Crossref
Alina Gherasim, Ahn Dao & Jonathan A Bernstein. (2018) Confounders of severe asthma: diagnoses to consider when asthma symptoms persist despite optimal therapy. World Allergy Organization Journal 11, pages 29.
Crossref
Crossref
E. V. Nosulya & I. A. Kim. (2017) The use of modern topical medications for the stepwise treatment of allergic rhinitis: the effectiveness and prospects for the further extension of their application. Vestnik otorinolaringologii 82:2, pages 65.
Crossref
Crossref
Brooke Harrow, Ahmad R. Sedaghat, Amanda Caldwell-Tarr & Robert Dufour. (2016) A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines. Journal of Managed Care & Specialty Pharmacy, pages 1-11.
Crossref
Crossref
Eli O. Meltzer, Dana Wallace, Mark Dykewicz & Lucy Shneyer. (2016) Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds?. The Journal of Allergy and Clinical Immunology: In Practice 4:4, pages 682-688.e6.
Crossref
Crossref
Erminia Ridolo, Marcello Montagni, Valerie Melli, Laura Bonzano, Cristoforo Incorvaia & Giorgio Walter Canonica. (2015) A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. Therapeutic Delivery 6:6, pages 653-659.
Crossref
Crossref
William E. Berger & Eli O. Meltzer. (2015) Intranasal Spray Medications for Maintenance Therapy of Allergic Rhinitis. American Journal of Rhinology & Allergy 29:4, pages 273-282.
Crossref
Crossref
Kari R. Brown & Jonathan A. Bernstein. (2015) Clinically relevant outcome measures of novel pharmacotherapy for nonallergic rhinitis. Current Opinion in Allergy & Clinical Immunology 15:3, pages 204-212.
Crossref
Crossref
N. G. Papadopoulos, J. A. Bernstein, P. Demoly, M. Dykewicz, W. Fokkens, P. W. Hellings, A. T. Peters, C. Rondon, A. Togias & L. S. Cox. (2015) Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy 70:5, pages 474-494.
Crossref
Crossref
Fulvio Braido, Federica Arcadipane, Fiorenza Marugo, Mituki Hayashi & Ruby Pawankar. (2014) Allergic rhinitis. Current Opinion in Allergy & Clinical Immunology 14:2, pages 168-176.
Crossref
Crossref
. (2014) Azelastine and fluticasone nasal spray: any advantage?. Drug and Therapeutics Bulletin 52:2, pages 21-24.
Crossref
Crossref